Background and future considerations for human cord blood hematopoietic cell transplantation, including economic concerns

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cord blood (CB) has been used since 1988 as a source of hematopoietic stem cells (HSCs) and progenitor cells for hematopoietic cell transplantation (HCT) to treat patients with malignant and nonmalignant disorders. CB has both advantages and disadvantages when compared with other tissue sources of HSCs such as bone marrow and mobilized peripheral blood, which are also being used in the setting of HCT. This short review focuses on some historical information, as well as current efforts that are being assessed to enhance the efficacy of CB HCT. Also of importance are the costs of CB, and the feasibility and economics of using such to be identified, and newly confirmed improvements worldwide for the greatest number of patients. In this context, simple methods that would not necessarily entail the need for selected cell-processing facilities to ex vivo expand or improve the CB graft's functional activity may be of interest, with one such possibility being the use of an orally active inhibitor of the enzyme dipeptidylpeptidase 4, alone or in combination with other new and innovative approaches for improving HSC engraftment and in vivo repopulating capability of CB.

Original languageEnglish
Pages (from-to)103-110
Number of pages8
JournalStem Cells and Development
Volume22
Issue numberSUPPL.1
DOIs
StatePublished - Dec 1 2013

Fingerprint

Cell Transplantation
Fetal Blood
Blood Cells
Economics
Hematopoietic Stem Cells
Enzyme Inhibitors
Bone Marrow
Transplants
Costs and Cost Analysis

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Hematology

Cite this

@article{2b4b894bd46946f4a6760463309c9cf4,
title = "Background and future considerations for human cord blood hematopoietic cell transplantation, including economic concerns",
abstract = "Cord blood (CB) has been used since 1988 as a source of hematopoietic stem cells (HSCs) and progenitor cells for hematopoietic cell transplantation (HCT) to treat patients with malignant and nonmalignant disorders. CB has both advantages and disadvantages when compared with other tissue sources of HSCs such as bone marrow and mobilized peripheral blood, which are also being used in the setting of HCT. This short review focuses on some historical information, as well as current efforts that are being assessed to enhance the efficacy of CB HCT. Also of importance are the costs of CB, and the feasibility and economics of using such to be identified, and newly confirmed improvements worldwide for the greatest number of patients. In this context, simple methods that would not necessarily entail the need for selected cell-processing facilities to ex vivo expand or improve the CB graft's functional activity may be of interest, with one such possibility being the use of an orally active inhibitor of the enzyme dipeptidylpeptidase 4, alone or in combination with other new and innovative approaches for improving HSC engraftment and in vivo repopulating capability of CB.",
author = "Hal Broxmeyer and Sherif Farag",
year = "2013",
month = "12",
day = "1",
doi = "10.1089/scd.2013.0382",
language = "English",
volume = "22",
pages = "103--110",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "SUPPL.1",

}

TY - JOUR

T1 - Background and future considerations for human cord blood hematopoietic cell transplantation, including economic concerns

AU - Broxmeyer, Hal

AU - Farag, Sherif

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Cord blood (CB) has been used since 1988 as a source of hematopoietic stem cells (HSCs) and progenitor cells for hematopoietic cell transplantation (HCT) to treat patients with malignant and nonmalignant disorders. CB has both advantages and disadvantages when compared with other tissue sources of HSCs such as bone marrow and mobilized peripheral blood, which are also being used in the setting of HCT. This short review focuses on some historical information, as well as current efforts that are being assessed to enhance the efficacy of CB HCT. Also of importance are the costs of CB, and the feasibility and economics of using such to be identified, and newly confirmed improvements worldwide for the greatest number of patients. In this context, simple methods that would not necessarily entail the need for selected cell-processing facilities to ex vivo expand or improve the CB graft's functional activity may be of interest, with one such possibility being the use of an orally active inhibitor of the enzyme dipeptidylpeptidase 4, alone or in combination with other new and innovative approaches for improving HSC engraftment and in vivo repopulating capability of CB.

AB - Cord blood (CB) has been used since 1988 as a source of hematopoietic stem cells (HSCs) and progenitor cells for hematopoietic cell transplantation (HCT) to treat patients with malignant and nonmalignant disorders. CB has both advantages and disadvantages when compared with other tissue sources of HSCs such as bone marrow and mobilized peripheral blood, which are also being used in the setting of HCT. This short review focuses on some historical information, as well as current efforts that are being assessed to enhance the efficacy of CB HCT. Also of importance are the costs of CB, and the feasibility and economics of using such to be identified, and newly confirmed improvements worldwide for the greatest number of patients. In this context, simple methods that would not necessarily entail the need for selected cell-processing facilities to ex vivo expand or improve the CB graft's functional activity may be of interest, with one such possibility being the use of an orally active inhibitor of the enzyme dipeptidylpeptidase 4, alone or in combination with other new and innovative approaches for improving HSC engraftment and in vivo repopulating capability of CB.

UR - http://www.scopus.com/inward/record.url?scp=84890923601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890923601&partnerID=8YFLogxK

U2 - 10.1089/scd.2013.0382

DO - 10.1089/scd.2013.0382

M3 - Article

C2 - 24304086

AN - SCOPUS:84890923601

VL - 22

SP - 103

EP - 110

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - SUPPL.1

ER -